Gate Bioscience, a privately held drug discovery company, announced Monday that it has expanded its research and licensing agreement with Eli Lilly (NYSE: LLY) in a deal now potentially worth more than $870 million. The original agreement, announced in July 2025, was worth up to $856 million. The expansion adds one drug target, with an option to add a second.
Gate will receive an upfront payment and research funding for the added target, plus an additional payment if the second target is selected. Neither company disclosed the size of the upfront payment. Gate is also eligible for milestone payments and royalties on global sales of any products that result.
The science behind the partnership takes a different approach to disease. Gate uses its platform to discover oral small-molecule drugs designed to eliminate proteins that have been difficult to target with existing medicines. Many conventional drugs work by blocking a protein’s activity, but some disease-driving proteins offer no good place for a drug to bind. A drug built to remove the protein altogether can reach targets once considered out of reach.
The two companies have split the work along familiar lines. Gate leads discovery, while Lilly takes over late-stage preclinical and clinical development, manufacturing, and commercialization. Lilly holds exclusive worldwide rights to products developed against the selected targets.
The deal fits a pattern in Lilly’s strategy this year. The company has acquired Merida Biosciences, which is developing biologics that eliminate disease-causing autoantibodies, and AtaiBeckley, a clinical-stage mental health company, while also signing earlier-stage platform partnerships like this one. Buying finished assets and renting promising discovery engines are two ways of filling the same pipeline.
The headline number deserves context. The expansion lifts the potential value by only about $14 million over the original agreement, which shows how these figures work. Partnership values are usually quoted at their maximum, with most of the money tied to development and sales milestones that may never be paid. The undisclosed upfront payment is the figure that actually reaches the company’s balance sheet.
The same partnership playbook is open to smaller companies pursuing oral small-molecule medicines. Cocrystal Pharma, which uses a structure-based discovery platform to develop antiviral drugs, and Cardiff Oncology, whose lead candidate onvansertib is an oral small molecule being studied in colorectal cancer, work in different therapeutic areas than Gate, and neither focuses on protein elimination. But both illustrate the model investors are watching: a differentiated discovery approach or oral drug candidate that could eventually attract a larger development partner.
For investors tracking small and microcap biotech, the takeaway cuts both ways. Large pharma remains willing to sign collaborations worth hundreds of millions of dollars with private platform companies before any drug reaches the clinic, a sign of continued appetite for differentiated discovery technology. But a platform deal is not an approved product. The upfront cash, the pace of milestone payments, and whether the partner keeps selecting targets matter most, and investors weighing smaller developers with similar partnership ambitions should read the fine print on all three.
